Analyst Upgrades Catalyst Pharmaceuticals to Overweight with New Price Target of 34
On March 1, 2024, Cantor Fitzgerald analyst Charles Duncan reaffirmed his positive stance on Catalyst Pharmaceuticals (NASDAQ:CPRX), upgrading the stock ...
On March 1, 2024, Cantor Fitzgerald analyst Charles Duncan reaffirmed his positive stance on Catalyst Pharmaceuticals (NASDAQ:CPRX), upgrading the stock ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.